Subgroup classification of receptor tyrosine kinase (RTK) pathway activation in KRAS-mutated metastatic carcinoma

被引：0
|
作者：
Wang, Y. [1 ]
Windham, J. P. [1 ]
Samul, R. A. [1 ]
Sanidad, M. A. [1 ]
Farooqui, A. [1 ]
Gorman, B. M. [1 ]
Kelly, J. C. [1 ]
Meloni-Ehrig, A. M. [1 ]
Jones, D. [1 ]
机构：
[1] Quest Diagnost Nichols Inst, Chantilly, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18019
引用
收藏
页数：1
相关论文
共 50 条
  • [41] KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis
    Li, W.
    Shi, Q.
    Wang, W.
    Liu, J.
    Ren, J.
    Li, Q.
    Hou, F.
    COLORECTAL DISEASE, 2014, 16 (11) : O370 - O378
  • [42] A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)
    Lenz, Heinz-Josef
    Kasi, Anup
    Mendelsohn, Lawrence
    Cannon, Timothy Lewis
    Starr, Jason S.
    Hubbard, Joleen M.
    Bekaii-Saab, Tanios S.
    Ridinger, Maya
    Samuelsz, Errin
    Ruffner, Katherine L.
    Erlander, Mark G.
    Ahn, Daniel H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [43] Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia
    D H Christiansen
    M K Andersen
    F Desta
    J Pedersen-Bjergaard
    Leukemia, 2005, 19 : 2232 - 2240
  • [44] Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia
    Christiansen, DH
    Andersen, MK
    Desta, F
    Pedersen-Bjergaard, J
    LEUKEMIA, 2005, 19 (12) : 2232 - 2240
  • [45] Insulin receptor tyrosine kinase substrate activates EGFR/ERK signalling pathway and promotes cell proliferation of hepatocellular carcinoma
    Wang, Yu-Ping
    Huang, Li-Yu
    Sun, Wei-Ming
    Zhang, Zhuang-Zhuang
    Fang, Jia-Zhu
    Wei, Bao-Feng
    Wu, Bing-Hao
    Han, Ze-Guang
    CANCER LETTERS, 2013, 337 (01) : 96 - 106
  • [46] Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma
    Bongarzone, I
    Fugazzola, L
    Vigneri, P
    Mariani, L
    Mondellini, P
    Pacini, F
    Basolo, F
    Pinchera, A
    Pilotti, S
    Pierotti, MA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05): : 2006 - 2009
  • [47] Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
    Steffen Weikert
    Carsten Kempkensteffen
    Jonas Busch
    Manfred Johannsen
    Viktor Grünwald
    Kaja Zimmermann
    Anne Flörcken
    Jörg Westermann
    Lisa Weinkauf
    Kurt Miller
    Ulrich Keilholz
    World Journal of Urology, 2013, 31 : 805 - 809
  • [48] Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
    Weikert, Steffen
    Kempkensteffen, Carsten
    Busch, Jonas
    Johannsen, Manfred
    Gruenwald, Viktor
    Zimmermann, Kaja
    Floercken, Anne
    Westermann, Joerg
    Weinkauf, Lisa
    Miller, Kurt
    Keilholz, Ulrich
    WORLD JOURNAL OF UROLOGY, 2013, 31 (04) : 805 - 809
  • [49] Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306
    Pietrantonio, F.
    Garassino, M. C.
    Torri, V.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2771 - 2772
  • [50] Tyrosine kinase/p21(ras)/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells
    Migliaccio, A
    DiDomenico, M
    Castoria, G
    deFalco, A
    Bontempo, P
    Nola, E
    Auricchio, F
    EMBO JOURNAL, 1996, 15 (06): : 1292 - 1300
12345